Oral diabetes is no joke, but so are the risks of cancer associated with medication that's supposed to combat the former. Takeda Pharmaceutical Company, a Japanese firm with an American subsidiary, had to pay $2.4 billion to settle an estimated 8,000 lawsuits over the company's oral diabetes medication Actos (pioglitazone) in 2015. Takeda was found guilty of understating the risks of bladder cancer related to the drug. Plaintiffs claimed that Takeda misled the public on Actos' benefits and overlooked side effects such as bladder cancer as discovered in clinical trials.